Vertex’s copay assistance changes add an undue burden for people living with an already expensive, challenging lifelong disease.
Bill will jump-start rebuilding of the antibiotics pipeline that is vital to stave off a looming pandemic.
Results show that people on Trikafta® enrolled in the six-week study were able to safely stop taking one of the two common CF medications without negatively affecting their health.
The Cystic Fibrosis Foundation is providing up to $5 million to develop a method to deliver a healthy copy of the CFTR gene into the lung cells of people with CF that is unlikely to trigger an immune system response.
Addressing variability in newborn screening can prevent missed diagnoses and delays in early care intervention.
Orkambi® is now approved for use in children with cystic fibrosis ages 1-2 years who have two F508del mutations. This is the only modulator available to very young children with these mutations.
CEO pledge is part of the Foundation’s ongoing commitment to strengthen the organization and better serve all people with CF
The law signals major improvements in health care affordability for people with CF.
The cystic fibrosis care model is evolving to support people living longer with CF and their increasingly diverse health needs. Catalyzed by the approval of Trikafta® and the COVID-19 pandemic, this adaptive and personalized care model encompasses novel ways to connect clinicians and patients.